Tositumomab
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
| - | {| class="wikitable" border="1" width=" | + | {| class="wikitable" border="1" width="60%" style="text-align:center" |
|- | |- | ||
! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref> | ! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref> | ||
Revision as of 07:17, 6 December 2010
Pharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | 205800 | Ibritumomab |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Protein Binding (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | 206 | Ibritumomab |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | Ibritumomab |
| Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
